MedeliX
Start asking

lasmiditan

Rayvow · ATC code N02CC08

Key facts
Active substance
lasmiditan
Drug class
Antimigraine
ATC code
N02CC08
Authorisation
centrally authorised across the EU (EMA)
Dosage forms
RAYVOW 50 mg film-coated tablets / RAYVOW 100 mg film-coated tablets / RAYVOW 200 mg film-coated tablets
Marketing authorisation holder
Eli Lilly Nederland B.V.
Information as of
2026-10-28

Key facts

Lasmiditan is a serotonin 5-HT1F receptor agonist for the acute treatment of the headache phase of migraine attacks with or without aura in adults (Rayvow, film-coated tablets).

What it is used for

  • Acute treatment of the headache phase of migraine attacks, with or without aura, in adults.

Dosing

  • Recommended initial dose 100 mg; if necessary increase to 200 mg for greater efficacy or decrease to 50 mg for greater tolerability.
  • If the headache recurs within 24 hours of an initial response to 50 mg or 100 mg, a second dose of the same strength may be taken, no sooner than 2 hours after the first.
  • No more than 200 mg in 24 hours; with or without food.
  • No dose adjustment in elderly patients, renal impairment, or mild to moderate hepatic impairment; not recommended in severe hepatic impairment.

Contraindications

  • See the full text.

Important warnings

  • CNS effects and driving impairment: do not drive or do tasks needing heightened attention until at least 8 hours after each dose; patients who cannot follow this should not take lasmiditan.
  • Serotonin syndrome may occur, especially with other serotonergic medicines; discontinue if suspected.
  • Caution with CNS depressants.
  • Medication overuse headache may occur; treatment should then be discontinued.

Side effects

  • Most common: dizziness (19.9 %), somnolence (7.8 %), fatigue (7.7 %), paraesthesia (6.8 %), nausea (4.9 %), vertigo (2.6 %), hypoaesthesia (2.5 %) and muscular weakness (2.3 %); most were dose-related.
  • Others: hypersensitivity, confusion, hallucinations, palpitations, visual impairment; rarely serotonin syndrome.

Interactions

  • Heart-rate-lowering medicines: additional heart rate lowering with propranolol.
  • Serotonergic medicines (e.g. SSRIs, SNRIs, TCAs) increase the risk of serotonin syndrome; limited experience with triptans in temporal proximity.
  • Increases exposure of P-gp substrates (dabigatran approximately 25%); caution with narrow-therapeutic-index P-gp substrates such as digoxin.

Pregnancy and breastfeeding

  • Not recommended during pregnancy.
  • Breast-feeding: weigh benefit and risk; infant exposure can be minimised by avoiding breast-feeding for 24 hours after treatment.

Summary of the official product information, written with AI on 2026-10-29. Every number was checked automatically against the original text. Not reviewed by a physician – the full official text is authoritative.

Full official text →

Common questions – ask Medelix

For patients

Package leaflet, verbatim

This product has no separate US patient information.

Authorisation and brand names by country

Medicines with exactly this active-substance composition, as listed in the national registers – alphabetical and without ranking. Whether a product is currently available is not shown here.

EU – centrally authorised (all member states)

  • RayvowEli Lilly Nederland B.V. · EMEA/H/C/005332

Source: European Medicines Agency (EMA), product information

Brand names in 3 more European countries
Iceland
Rayvow
Liechtenstein
Rayvow
Norway
Rayvow

EMA – Article 57 product data (EU/EEA), 2026-10-29

Medelix receives no money from pharmaceutical companies. Brand names are listed alphabetically and without ranking.

Other substances in the same group

Another question about this substance?

Medelix answers clinical questions from guidelines, studies and product information – every claim with its source.

Sources

  1. European Medicines Agency. Rayvow – EPAR, Product Information. 2026-10-28. https://www.ema.europa.eu/en/documents/product-information/rayvow-epar-product-information_en.pdf
  2. Wikidata (CC0): ATC N02CC.

Editorial: Medelix editorial team · last updated 2026-10-28 · How these pages are made · Report an error

Source: European Medicines Agency (EMA), product information. Not advertising, not a treatment recommendation. For questions about your own treatment, ask your doctor or pharmacist.